Cited by 1,296HIV/AIDS Research and InterventionsHIV/AIDS drug development and treatmentHIV Research and Treatment

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Tenofovir-based preexposure prophylaxis for HIV infection among African women.

Open access

Marrazzo, Jeanne M., Ramjee, Gita, Richardson, Barbra A., Gomez, Kailazarid, Mgodi, Nyaradzo, Nair, Gonasagrie, Palanee, Thesla, Nakabiito, Clemensia, van der Straten, Ariane, Noguchi, Lisa, Hendrix, Craig W., Dai, James Y., Ganesh, Shayhana, Mkhize, Baningi, Taljaard, Marthinette, Parikh, Urvi M., Piper, Jeanna, Mâsse, Benoît, Grossman, Cynthia, Rooney, James, Schwartz, Jill L., Watts, Heather, Marzinke, Mark A., Hillier, Sharon L., McGowan, Ian M., Chirenje, Z. Mike·2015·New England Journal of Medicine

DOI 10.1056/nejmoa1402269PMC PMC4341965

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Reproductive-age women need effective interventions to prevent the acquisition of human immunodeficiency virus type 1 (HIV-1) infection. METHODS: We conducted a randomized, placebo-controlled trial to assess daily treatment with oral tenofovir disoproxil fumarate (TDF), oral tenofovir-emtricitabine (TDF-FTC), or 1% tenofovir (TFV) vaginal gel as preexposure prophylaxis against HIV-1 infection in women in South Africa, Uganda, and Zimbabwe. HIV-1 testing was performed monthly, and plasma TFV levels were assessed quarterly. RESULTS: Of 12,320 women who were screened, 5029 were enrolled in the study. The rate of retention in the study was 91% during 5509 person-years of follow-up. A total of 312 HIV-1 infections occurred; the incidence of HIV-1 infection was 5.7 per 100 person-years. In the modified intention-to-treat analysis, the effectiveness was -49.0% with TDF (hazard ratio for infection, 1.49; 95% confidence interval [CI], 0.97 to 2.29), -4.4% with TDF-FTC (hazard ratio, 1.04; 95% CI, 0.73 to 1.49), and 14.5% with TFV gel (hazard ratio, 0.85; 95% CI, 0.61 to 1.21). In a random sample, TFV was detected in 30%, 29%, and 25% of available plasma samples from participants randomly assigned to receive TDF, TDF-FTC, and TFV gel, respectively. Independent predictors of TFV detection included being married, being older than 25 years of age, and being multiparous. Detection of TFV in plasma was negatively associated with characteristics predictive of HIV-1 acquisition. Elevations of serum creatinine levels were seen more frequently among participants randomly assigned to receive oral TDF-FTC than among those assigned to receive oral placebo (1.3% vs. 0.2%, P=0.004). We observed no significant differences in the frequencies of other adverse events. CONCLUSIONS: None of the drug regimens we evaluated reduced the rates of HIV-1 acquisition in an intention-to-treat analysis. Adherence to study drugs was low. (Funded by the National Institutes of Health; VOICE ClinicalTrials.gov number, NCT00705679.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1402269

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., Goicochea, P., Casapía, M., Guanira-Carranza, J. V., Ramirez-Cardich, M. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1011205 · Cited by 5,096
Self-citation
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Baeten, J. M., Donnell, D., Ndase, P., Mugo, N. R., Campbell, J. D., Wangisi, J., Tappero, J. W., Bukusi, E. A., Cohen, C. R., Katabira, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108524 · Cited by 3,256
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Abdool Karim, Q., Abdool Karim, S. S., Frohlich, J. A., Grobler, A. C., Baxter, C., Mansoor, L. E., Kharsany, A. B. M., Sibeko, S., Mlisana, K. P., Omar, Z., et al. (2010) · Science · doi:10.1126/science.1193748 · Cited by 2,435
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Thigpen, M. C., Kebaabetswe, P. M., Paxton, L. A., Smith, D. K., Rose, C. E., Segolodi, T. M., Henderson, F. L., Pathak, S. R., Soud, F. A., Chillag, K. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110711 · Cited by 1,996
Preexposure Prophylaxis for HIV Infection among African Women
Damme, L. V., Corneli, A. L., Ahmed, K., Agot, K. E., Lombaard, J. J., Kapiga, S., Malahleha, M., Owino, F., Manongi, R. N., Onyango, J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202614 · Cited by 1,633
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Choopanya, K., Martin, M., Suntharasamai, P., Sangkum, U., Mock, P. A., Leethochawalit, M., Chiamwongpaet, S., Kitisin, P., Natrujirote, P., Kittimunkong, S., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61127-7 · Cited by 1,463
A Case-Cohort Design for Epidemiologic Cohort Studies and Disease Prevention Trials
Prentice, R. L. (1986) · Biometrika · doi:10.1093/biomet/73.1.1 · Cited by 1,444
High Coverage of ART Associated with Decline in Risk of HIV Acquisition in Rural KwaZulu-Natal, South Africa
Tanser, F. C., Bärnighausen, T., Grapsa, E., Zaidi, J., & Newell, M. (2013) · Science · doi:10.1126/science.1228160 · Cited by 797
Web Resources for HIV Type 1 Genotypic-Resistance Test Interpretation
Liu, T. F., & Shafer, R. W. (2006) · Clinical Infectious Diseases · doi:10.1086/503914 · Cited by 661
Complex Surveys: A Guide to Analysis Using R
Lumley, T. (2010) · doi:10.1002/9780470580066 · Cited by 647

Flagged first, then by citations

Show all 19 references

Sorted by citations

Items 701–800 of 999

Does the Ring Work? Perceptions and Understanding of the Efficacy of a Dapivirine Vaginal Ring for HIV Prevention Amongst Women in a Placebo-Controlled Trial
Etima, J., Katz, A. W. K., Duby, Z., Garcia, M., Palanee‐Phillips, T., Reddy, K., Mathebula, F., Zimba, C. C., Mansoor, L. E., Singh, D., et al. (2021) · AIDS and Behavior · doi:10.1007/s10461-021-03512-5 · Cited by 11
Unlocking the complexity of HIV and Mycobacterium tuberculosis coinfection
Scully, E. P., & Bryson, B. D. (2021) · Journal of Clinical Investigation · doi:10.1172/jci154407 · Cited by 12
Antibody-mediated immune exclusion of HIV
Ruprecht, R. M., & Lakhashe, S. K. (2017) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000369 · Cited by 11
Feasibility, Acceptability, and Adherence with Short-Term HIV Preexposure Prophylaxis in Female Sexual Partners of Migrant Miners in Mozambique
Lahuerta, M., Zerbe, A., Baggaley, R. C., Falcão, J., Ahoua, L., DiMattei, P., Morales, F., Ramiro, I., & El-Sadr, W. M. (2017) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001518 · Cited by 11
Epithelial Cells and Fibroblasts from the Human Female Reproductive Tract Accumulate and Release TFV and TAF to Sustain Inhibition of HIV Infection of CD4+ T cells
Shen, Z., Rodríguez‐García, M., Patel, M. V., Bodwell, J. E., & Wira, C. R. (2019) · Scientific Reports · doi:10.1038/s41598-018-38205-y · Cited by 11
Antiretroviral Medications for the Prevention of HIV Infection
Heendeniya, A., & Bogoch, I. I. (2019) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2019.04.002 · Cited by 12
Parallel Approximation Algorithms
Mayr, E. W. (1988) · Future Generation Computer Systems · Cited by 11
Distinct Pharmacodynamic Activity of Rilpivirine in Ectocervical and Colonic Explant Tissue
Dezzutti, C. S., Else, L., Yandura, S. E., Shetler, C., Russo, J., Back, D. J., & McGowan, I. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00167-16 · Cited by 10
Social and behavioural research prospects for sexually transmissible infection prevention in the era of advances in biomedical approaches
Hogben, M., Dittus, P., Leichliter, J. S., & Aral, S. O. (2020) · Sexual Health · doi:10.1071/sh19105 · Cited by 11
Feasibility, Acceptability, and Preliminary Efficacy of a Gamified Mobile Health Contingency Management Intervention for PrEP Adherence Among Black MSM
Mitchell, J. T., Burns, C. M., Atkinson, B., Cottrell, M. L., Frye, J. K., McKellar, M., Kashuba, A. D. M., McClernon, F. J., & Okeke, N. L. (2022) · AIDS and Behavior · doi:10.1007/s10461-022-03675-9 · Cited by 10
High study participation but diverging adherence levels: qualitatively unpacking PrEP use among adolescent girls and young women over two years in Eastern Cape, South Africa
Krogstad, E. A., de Vos, L., Atujuna, M., Fynn, L., Mugore, M., Mabandla, S., Hosek, S., Celum, C., Bekker, L., Daniels, J., et al. (2023) · Journal of Behavioral Medicine · doi:10.1007/s10865-023-00462-2 · Cited by 10
Awareness and willingness to use pre‐exposure prophylaxis among the University of Zambia students: A cross‐sectional study
Kampamba, M., Nelumbu, N. N., Hikaambo, C. N., Mudenda, S., Hangoma, J. M., Kunda, M., Mufwambi, W., Hamachila, A., & Mukosha, M. (2024) · Health Science Reports · doi:10.1002/hsr2.70060 · Cited by 10
Trajectories of Adherence to Oral Pre-exposure Prophylaxis and Risks of HIV and Sexually Transmitted Infections
Unigwe, I. F., Goodin, A. J., Lo‐Ciganic, W., Cook, R. L., Janelle, J. W., & Park, H. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae569 · Cited by 11
Driving progress towards PrEP equity: Key changes in the 2025 BASHH / BHIVA UK PrEP guidelines
Clutterbuck, D., Brady, M., & Rodger, A. J. (2025) · HIV Medicine · doi:10.1111/hiv.70043 · Cited by 9
Safer Conception Strategies for HIV-Serodiscordant Couples: How Safe Is Safe Enough?: Table 1.
Ciaranello, A. L., & Matthews, L. T. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiv275 · Cited by 10
Antiretroviral drug use and HIV drug resistance in female sex workers in Tanzania and the Dominican Republic
Grant‐McAuley, W., Fogel, J. M., Galai, N., Clarke, W. A., Breaud, A. R., Marzinke, M. A., Mbwambo, J. K. K., Likindikoki, S. L., Aboud, S., Donastorg, Y., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0240890 · Cited by 10
Temporal and spatial monitoring of HIV prevalence and incidence rates using geospatial models: Results from South African women
Wand, H. C., Morris, N., & Reddy, T. (2021) · Spatial and Spatio-temporal Epidemiology · doi:10.1016/j.sste.2021.100413 · Cited by 10
Use of Interventions to Overcome Medication Non-Adherence
Saha, S. K., Adhikary, A., Jha, A. K., & Mehta, V. K. (2021) · International Journal of Asian Business and Information Management · doi:10.4018/ijabim.20210701.oa18 · Cited by 10
Women for science and science for women: Gaps, challenges and opportunities towards optimizing pre-exposure prophylaxis for HIV-1 prevention
Karim, Q. A., Archary, D., Barré‐Sinoussi, F., Broliden, K., Cabrera, C., Chiodi, F., Fidler, S. J., Gengiah, T. N., Herrera, C., Kharsany, A. B. M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1055042 · Cited by 10
Integration of sexually transmitted infection and HIV pre-exposure prophylaxis services in sub-Saharan Africa: a scoping review
Anand, P., Wu, L., & Mugwanya, K. K. (2023) · Frontiers in Reproductive Health · doi:10.3389/frph.2023.944372 · Cited by 10
“Emotional stress is more detrimental than the virus itself”: A qualitative study to understand HIV testing and pre‐exposure prophylaxis (PrEP) use among internal migrant men in South Africa
Nardell, M. F., Govathson, C., Garnier, S., Watts, A., Babalola, D., Ngcobo, N., Long, L. C., Lurie, M. N., Miot, J., Pascoe, S. J. S., et al. (2024) · Journal of the International AIDS Society · doi:10.1002/jia2.26225 · Cited by 9
Antiretroviral pre-exposure prophylaxis: A new opportunity to slow HIV spread in India
Mayer, K. H., Chandhiok, N., & Thomas, B. E. (2016) · The Indian Journal of Medical Research · doi:10.4103/0971-5916.180194 · Cited by 10
CROI 2015: Advances in HIV Testing and Prevention Strategies.
Buchbinder, S., & Liu, A. (2015) · Europe PMC (PubMed Central) · Cited by 10
Published randomized trials performed in Sub-Saharan Africa focus on high-burden diseases but are frequently funded and led by high-income countries
Ndounga‐Diakou, L. A., Ntoumi, F., Ravaud, P., & Boutron, I. (2016) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2016.10.008 · Cited by 10
Acceptability of and Adherence to an Antiretroviral-Based Vaginal Microbicide among Pregnant Women in the United States
Montgomery, E., Noguchi, L., Dai, J. Y., Pan, J., Biggio, J., Hendrix, C. W., Isaacs, K. M., Watts, D. H., Schwartz, J. L., Piper, J. M., et al. (2017) · AIDS and Behavior · doi:10.1007/s10461-017-1811-9 · Cited by 10
Contraception and PrEP in South African Hair Salons: Owner, Stylist, and Client Views
Bassett, I. V., Xu, A., Govere, S., Thulare, H., Frank, S. C., Psaros, C., & Parker, R. A. (2018) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001794 · Cited by 10
Vaginal washing and lubrication among female sex workers in the Mexico-US border region: implications for the development of vaginal PrEP for HIV prevention
Pines, H. A., Semple, S. J., Strathdee, S. A., Hendrix, C. W., Vera, A., Gorbach, P. M., Magis-Rodríguez, C. L., Martı́nez, G., & Patterson, T. L. (2018) · BMC Public Health · doi:10.1186/s12889-018-5946-z · Cited by 10
Engaging study participants in interpreting results: lessons from the TRIO study in Kenya and South Africa
Agot, K. E., Minnis, A. M., Manenzhe, K. N., Browne, E. N., Ahmed, K., Okello, T., & van der Straten, A. (2019) · International Journal of Women s Health · doi:10.2147/ijwh.s193905 · Cited by 10
Rectal Microbiome Alterations Associated With Oral Human Immunodeficiency Virus Pre-Exposure Prophylaxis
Fulcher, J. A., Li, F., Cook, R., Zabih, S., Louie, A., Okochi, H., Tobin, N. H., Gandhi, M., SHOPTAW, S. J., Gorbach, P. M., et al. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz463 · Cited by 10
Implementation of a fidelity monitoring process to assess delivery of an evidence-based adherence counseling intervention in a multi-site biomedical HIV prevention study
Balán, I. C., Lentz, C. L., Giguere, R., Mayo, A., Rael, C. T., Soto-Torres, L. E., Palanee‐Phillips, T., Mgodi, N. M., Hillier, S. L., Baeten, J. M., et al. (2020) · AIDS Care · doi:10.1080/09540121.2019.1709614 · Cited by 11
The Economics of the Global Response to HIV/AIDS
Haacker, M. (2016) · doi:10.1093/acprof:oso/9780198718048.001.0001 · Cited by 10
Predicting HIV Pre-exposure Prophylaxis Efficacy for Women using a Preclinical Pharmacokinetic-Pharmacodynamic In Vivo Model
Wahl, A. R., Ho, P. T., Denton, P. W., Garrett, K. L., Hudgens, M. G., Swartz, G. M., O’Neill, C., Veronese, F. D. M., Kashuba, A. D. M., & García, J. V. (2017) · Scientific Reports · doi:10.1038/srep41098 · Cited by 10
New anionic carbosilane dendrons functionalized with a DO3A ligand at the focal point for the prevention of HIV-1 infection
Moreno, S., Sepúlveda‐Crespo, D., de la Mata, F. J., Gómez, R., & Muñoz‐Fernández, M. Á. (2017) · Antiviral Research · doi:10.1016/j.antiviral.2017.08.009 · Cited by 10
HIV preexposure prophylaxis: An essential, safe and effective prevention tool for sexual health
Siguier, M., & Molina, J. (2018) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2018.01.009 · Cited by 12
Qualitative exploration of intrinsic and extrinsic factors that influence acceptability of semisoft vaginal suppositories
Zaveri, T. D., Powell, K., Guthrie, K. M., Bakke, A. J., Ziegler, G. R., & Hayes, J. E. (2018) · BMC Women s Health · doi:10.1186/s12905-018-0657-2 · Cited by 10
An Overview of Social and Behavioral Determinants of STI
Hogben, M., Leichliter, J. S., & Aral, S. O. (2020) · Springer eBooks · doi:10.1007/978-3-030-02200-6_3 · Cited by 9
Development and Evaluation of Nanoparticles-in-Film Technology to Achieve Extended In Vivo Exposure of MK-2048 for HIV Prevention
Tong, X., Patel, S. K., Li, J., Patton, D. L., Xu, E., Anderson, P. L., Parikh, U. M., SWEENEY, Y. T. C., Strizki, J., Hillier, S. L., et al. (2022) · Polymers · doi:10.3390/polym14061196 · Cited by 9
Factors Associated with Usage of Oral-PrEP among Female Sex Workers in Nairobi, Kenya, Assessed by Self-Report and a Point-of-Care Urine Tenofovir Immunoassay
Shah, P., Spinelli, M. A., Irungu, E., Kabuti, R., Ngurukiri, P., Babu, H., Kungu, M., Champions, T. M. F. S., Nyabuto, C., Mahero, A., et al. (2024) · AIDS and Behavior · doi:10.1007/s10461-024-04455-3 · Cited by 9
Sub-Saharan Africa's Contribution to Clinical Trials in International Acute Coronary Syndromes and Heart Failure Guidelines
Hudson, J. A., Sanga, L. A., Jobe, M., Etyang, A. O., McAllister, D. W., Perel, P., Shah, A. S. V., & Ogola, E. N. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.101383 · Cited by 9
Assessing PrEP Initiation and Adherence Among High-Risk, Sexually Active Adolescents and Young Adults: A Population-Based Prospective Study Across Diverse Service Delivery Models in a High HIV Prevalent District in South Africa
Nicol, E., Basera, W., Turawa, E. B., Lombard, C. J., Funani, N., Chavhalala, D., & the SHeS’Cap-PrEP group (2025) · AIDS and Behavior · doi:10.1007/s10461-025-04719-6 · Cited by 9
“It Was Not My Aim to Sleep There”: The Impact of Timing and Location of Sex on Adherence to Coitally-Dependent HIV Pre-exposure Prophylaxis
Scorgie, F., Stadler, J., Baron, D., Ju, S., Ikaneng, T., Mabude, Z., Makgopa, S., Malefo, M. A., Manenzhe, K. N., Mazibuko, T., et al. (2018) · AIDS and Behavior · doi:10.1007/s10461-018-2195-1 · Cited by 9
Development and initial validation of a simple tool to screen for partner support or opposition to HIV prevention product use
Tolley, E. E., Zissette, S., Martínez, A., Palanee‐Phillips, T., Mathebula, F., Tenza, S., Hartmann, M., & Montgomery, E. (2020) · PLoS ONE · doi:10.1371/journal.pone.0242881 · Cited by 8
Are We Hitting the Target? HIV Pre-Exposure Prophylaxis from 2012 to 2020 in the OPERA Cohort
Mounzer, K., Fusco, J. S., Hsu, R. K., Brunet, L., Vannappagari, V. X., Frost, K. R., Shaefer, M. S., Rinehart, A. R., Rawlings, K., & Fusco, G. (2021) · AIDS Patient Care and STDs · doi:10.1089/apc.2021.0064 · Cited by 9
Implementing pre-exposure prophylaxis for HIV prevention in women: the role of the obstetrician-gynecologist
Butler, S. K., Kislovskiy, Y., Bunge, K. E., & Wiesenfeld, H. C. (2021) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2021.12.263 · Cited by 9
A multi‐country cross‐sectional study to assess predictors of daily versus on‐demand oral pre‐exposure prophylaxis in youth from South Africa, Uganda and Zimbabwe
Dietrich, J. J., Ahmed, N., Webb, E. L., Tshabalala, G., Hornschuh, S., Mulaudzi, M., Atujuna, M., Stranix‐Chibanda, L., Nematadzira, T., Ssemata, A. S., et al. (2022) · Journal of the International AIDS Society · doi:10.1002/jia2.25975 · Cited by 9
Vaginal Prostate Specific Antigen (PSA) Is a Useful Biomarker of Semen Exposure Among HIV-Infected Ugandan Women
Woolf‐King, S. E., Muyindike, W. R., Hobbs, M. M., Kusasira, A., Fatch, R., Emenyonu, N. I., Johnson, M. O., & Hahn, J. A. (2016) · AIDS and Behavior · doi:10.1007/s10461-016-1433-7 · Cited by 9
Drug safety evaluation of oral tenofovir disoproxil fumarate-emtricitabine for pre-exposure prophylaxis for human immunodeficiency virus infection
Trang, T. P., Dong, B. J., Kojima, N., & Klausner, J. D. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1211108 · Cited by 9
Implementing Generalized Additive Models to Estimate the Expected Value of Sample Information in a Microsimulation Model: Results of Three Case Studies
Rabideau, D. J., Pei, P. P., Walensky, R. P., Zheng, A., & Parker, R. A. (2017) · Medical Decision Making · doi:10.1177/0272989x17732973 · Cited by 9
Vaginal progesterone to prevent preterm delivery among HIV-infected pregnant women in Zambia: A feasibility study
Price, J. T., Phiri, W. M., Freeman, B. L., Vwalika, B., Winston, J., Mabula‐Bwalya, C. M., Mulenga, H. B., & Stringer, J. S. A. (2020) · PLoS ONE · doi:10.1371/journal.pone.0224874 · Cited by 9
Examining the Safety, Pharmacokinetics, and Pharmacodynamics of a Rectally Administered IQP-0528 Gel for HIV Pre-Exposure Prophylaxis: A First-In-Human Study
Al‐khouja, A., Shieh, E. C., Fuchs, E. J., Marzinke, M. A., Bakshi, R. P., Hummert, P., Ham, A. S., Buckheit, K. W., Breakey, J., Weld, E. D., et al. (2020) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2020.0188 · Cited by 9
Integration of HIV Prevention With Sexual and Reproductive Health Services: Evidence for Contraceptive Options and HIV Outcomes Study Experience of Integrating Oral Pre-exposure HIV Prophylaxis in Family Planning Services in Lusaka, Zambia
Kasaro, M. P., Sindano, N., Chinyama, M., Mudenda, M., Chilaisha, F., Price, J. T., & Chileshe, M. (2021) · Frontiers in Reproductive Health · doi:10.3389/frph.2021.684717 · Cited by 9
Safety Assessment of Microbicide 2P23 on the Rectal and Vaginal Microbiota and Its Antiviral Activity on HIV Infection
Gao, Z., Fu, R., Li, X., Wang, J., & He, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.702172 · Cited by 9
Evaluation of tenofovir disoproxil fumarate loaded silver nanoparticle on testicular morphology in experimental type-2 diabetic rats
Olojede, S. O., Lawal, S. K., Dare, A., Naidu, E. C., Rennie, C. O., & Azu, O. O. (2022) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2022.2042009 · Cited by 9
BLOCKING CXCL9 DECREASES HIV-1 REPLICATION AND ENHANCES THE ACTIVITY OF PROPHYLACTIC ANTIRETROVIRALS IN HUMAN CERVICAL TISSUES
Macura, S., Lathrop, M., Gui, J., Doncel, G., Asin, S., & Rollenhagen, C. (2016) · Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000891 · Cited by 8
PrEP in Italy: The time may be ripe but who's paying the bill? A nationwide survey on physicians' attitudes towards using antiretrovirals to prevent HIV infection
Biagio, A. D., Riccardi, N., Signori, A., Maserati, R., Nozza, S., Gori, A., Bonora, S., Borderi, M., Ripamonti, D., Rossi, M. C., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181433 · Cited by 9
Exploring Sex, HIV and ‘Sensitive’ Space(s) Among Sexual and Gender Minority Young Adults in Thailand
Newman, P. A., Tepjan, S., & Rubincam, C. (2017) · Palgrave Macmillan UK eBooks · doi:10.1057/978-1-137-58614-8_5 · Cited by 9
Advancing HIV Biomedical Prevention Research for At-Risk Adolescents
Kapogiannis, B. G., Nelson, R. M., Siberry, G. K., Lee, S., & Hazra, R. (2018) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001853 · Cited by 9
Trajectory of use over time of an oral tablet and a rectal gel for HIV prevention among transgender women and men who have sex with men
Leu, C., Giguere, R., Bauermeister, J. A., Dolezal, C. L., Brown, W., Balán, I. C., Richardson, B. A., Piper, J. M., Lama, J. R., Cranston, R., et al. (2018) · AIDS Care · doi:10.1080/09540121.2018.1533223 · Cited by 8
Feasibility and Safety of IUD Insertion by Mid-Level Providers in Sub-Saharan Africa
Mhlanga, F., Balkus, J. E., Singh, D., Chappell, C. A., Kamira, B., Harkoo, I., Szydlo, D. W., Mukaka, S., Piper, J. M., & Hillier, S. L. (2019) · International Perspectives on Sexual and Reproductive Health · doi:10.1363/45e8019 · Cited by 9
In vitro Study on Synergistic Interactions Between Free and Encapsulated Q-Griffithsin and Antiretrovirals Against HIV-1 Infection
Minooei, F., Fried, J., Fuqua, J. L., Palmer, K. E., & Steinbach-Rankins, J. M. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s287310 · Cited by 9
Meeting report: South African Medical Research Council Standard of Care in Clinical Research in Low- And Middle-Income Settings Summit, November 2017
Miner, M. D., Bekker, L., Kredo, T., Bhagwandin, N., Corey, L., & Gray, G. (2021) · Trials · doi:10.1186/s13063-021-05754-z · Cited by 8
Condomless Sex With Virologically Suppressed HIV-Infected Individuals
Daar, E. S., & Corado, K. (2016) · JAMA · doi:10.1001/jama.2016.5636 · Cited by 9
Treatment as the Best Prevention: Twice-Yearly Lenacapavir, a Game Changer in Ending the AIDS Epidemic
Wen, Z., Shi, M., & Sun, C. (2024) · Viruses · doi:10.3390/v16091368 · Cited by 10
Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States
Brogan, A. J., Davis, A. E., Mellott, C. E., Fraysse, J., Metzner, A. A., & Oglesby, A. K. (2024) · PharmacoEconomics · doi:10.1007/s40273-023-01342-y · Cited by 9
HIV diagnosis during acute infection: implications of long-acting preexposure prophylaxis and other evolving challenges
Elliott, T., Bradshaw, D., & Fidler, S. J. (2025) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000919 · Cited by 8
The Need for Lenacapavir Compulsory Licences in Ending the HIV Epidemic
Hill, A. M., Siedner, M. J., Fairhead, C., & Venter, F. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf115 · Cited by 8
Biomedical Interventions for HIV Prevention and Control: Beyond Vaccination
Liao, Y., Wen, Z., Shi, M., Zou, H., & Sun, C. (2025) · Viruses · doi:10.3390/v17060756 · Cited by 11
Modelling the impact of initiation delay, duration and prior PrEP on the efficacy of post‐exposure prophylaxis containing a tenofovir/emtricitabine backbone
Zhang, L., Collins, S., Fox, J., & von Kleist, M. (2025) · Journal of the International AIDS Society · doi:10.1002/jia2.26454 · Cited by 8
Injectable and Implantable Antiretroviral Strategies for HIV Prevention
McGowan, I. (2015) · Future Virology · doi:10.2217/fvl.15.83 · Cited by 8
Brief Report: Anal Intercourse, HIV-1 Risk, and Efficacy in a Trial of a Dapivirine Vaginal Ring for HIV-1 Prevention
Peebles, K., van der Straten, A., Palanee‐Phillips, T., Reddy, K., Hillier, S. L., Hendrix, C. W., Harkoo, I., Mirembe, B. G., Jeenarain, N., Baeten, J. M., et al. (2019) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002253 · Cited by 8
Supporting the Art: Medication Adherence Patterns in Persons Prescribed Ingestible Sensor-enabled Oral Pre-Exposure Prophylaxis to Prevent Human Immunodeficiency Virus Infection
Browne, S. H., Vaida, F., Umlauf, A., Tucker, A. J., Blaschke, T. F., & Benson, C. A. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac280 · Cited by 8
Stakeholder perspectives on interventions to improve HIV pre-exposure prophylaxis uptake and continuation in Lesotho: A participant-ranked preferences study
Chebet, J. J., McMahon, S. A., Chase, R. P., Tarumbiswa, T., Maponga, C., Mandara, E., Bärnighausen, T., & Geldsetzer, P. (2023) · PLOS Global Public Health · doi:10.1371/journal.pgph.0001423 · Cited by 9
Confirmatory Factor Analysis and Validation of the Sexual and Reproductive Empowerment Scale for Adolescents and Young Adults in Kenya
Zia, Y., Upadhyay, U. D., Rhew, I. C., Kimanthi, S., Congo, O., Onono, M. A., Barnabas, R. V., Mugo, N., Bukusi, E. A., & Harrington, E. K. (2024) · Studies in Family Planning · doi:10.1111/sifp.12263 · Cited by 8
HPTN 083‐02: factors influencing adherence to injectable PrEP and retention in an injectable PrEP study
Psaros, C., Goodman, G. R., Lee, J. S., Rice, W. S., Kelley, C. F., Oyedele, T., Coelho, L. E., Phanuphak, N., Singh, Y., Middelkoop, K., et al. (2024) · Journal of the International AIDS Society · doi:10.1002/jia2.26252 · Cited by 8
Pharmacologic Prevention of Human Immunodeficiency Virus in Women
Hong, J. N., Farel, C. E., & Rahangdale, L. (2015) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000000170 · Cited by 8
Antiretroviral Drug Use in a Cross-Sectional Population Survey in Africa: NIMH Project Accept (HPTN 043)
Fogel, J. M., Clarke, W. A., Kulich, M., Piwowar‐Manning, E., Breaud, A. R., Olson, M. T., Marzinke, M. A., Laeyendecker, O. B., Fiamma, A., Donnell, D. J., et al. (2016) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001229 · Cited by 8
Contraceptive Use and Pregnancy Incidence Among Women Participating in an HIV Prevention Trial
Akello, C. A., Bunge, K. E., Nakabiito, C., Mirembe, B. G., Fowler, M. G., Mishra, A., Marrazzo, J. M., Chirenje, Z. M., Celum, C., & Balkus, J. E. (2017) · Journal of Women s Health · doi:10.1089/jwh.2016.5958 · Cited by 8
Acceptability of an open-label wait-listed trial design: Experiences from the PROUD PrEP study
Gafos, M., Brodnicki, E., Desai, M., McCormack, S., Nutland, W., Wayal, S., White, E., Wood, G., Barber, T., Bell, G., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0175596 · Cited by 8
Tailoring the Local HIV/AIDS Response to Local HIV/AIDS Epidemics
Wilson, D. P., & Taaffe, J. E. (2017) · World Bank, Washington, DC eBooks · doi:10.1596/978-1-4648-0524-0_ch8 · Cited by 8
НОВІТНІ МЕТОДИ СТРИМУВАННЯ ІНФЕКЦІЙ, ЩО ПЕРЕДАЮТЬСЯ СТАТЕВИМ ШЛЯХОМ
Mavrov, G. I., Shcherbakova, Y. V., & Osinska, T. V. (2019) · Інфекційні хвороби · doi:10.11603/1681-2727.2019.1.9933 · Cited by 8
A Caulobacter crescentus Microbicide Protects from Vaginal Infection with HIV-1 JR-CSF in Humanized Bone Marrow-Liver-Thymus Mice
Zuend, C. F., Nomellini, J. F., Smit, J., & Horwitz, M. S. (2019) · Journal of Virology · doi:10.1128/jvi.00614-19 · Cited by 8
Control of HIV/AIDS can be achieved with multi-strategies
Detels, R., Wu, J., & Wu, Z. (2019) · Global Health Journal · doi:10.1016/j.glohj.2019.06.001 · Cited by 8
Determinants of antenatal HIV testing in the opt-out approach in Nigeria: findings from the Nigerian Demographic and Health Survey
Udoh, E. E., & Ushie, B. A. (2019) · Journal of Biosocial Science · doi:10.1017/s0021932019000555 · Cited by 8
Coverage of Sex Acts by Event-Driven Pre-exposure Prophylaxis: A Sub-Study of the ANRS IPERGAY Trial
ANRS IPERGAY Study Group, Bauer, R., Netzer, E., Pintado, C., Capitant, C., Cua, É., Etien, N., Fonsart, J., Pialoux, G., Chidiac, C., et al. (2020) · AIDS and Behavior · doi:10.1007/s10461-020-02890-6 · Cited by 8
Mathematical Model Impact Analysis of a Real-Life Pre-exposure Prophylaxis and Treatment-As-Prevention Study Among Female Sex Workers in Cotonou, Benin
Geidelberg, L., Mitchell, K. M., Alary, M., Mboup, A., Béhanzin, L., Guédou, F. A., Geraldo, N., Goma‐Matsétsé, E., Giguère, K., Aza‐Gnandji, M., et al. (2020) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002535 · Cited by 9
Inflammation, HIV, and Immune Quiescence: Leveraging on Immunomodulatory Products to Reduce HIV Susceptibility
Cromarty, R. T., & Archary, D. (2020) · AIDS Research and Treatment · doi:10.1155/2020/8672850 · Cited by 8
Assessment of risk compensation following use of the dapivirine vaginal ring in southwestern Uganda
Kusemererwa, S., Abaasa, A. M., Kabarambi, A., Onyango, M., & Mugisha, J. O. (2021) · Sexually Transmitted Infections · doi:10.1136/sextrans-2020-054718 · Cited by 8
The Relationship Between HIV Pre-exposure Prophylaxis Stigma and Treatment Adherence Among Current HIV Pre-exposure Prophylaxis Users in the Southeastern U.S.
Gerwen, O. T. V., Yiğit, İ., Crockett, K. B., & Turan, B. (2022) · AIDS and Behavior · doi:10.1007/s10461-022-03883-3 · Cited by 9
Self-reported and pill count measures of adherence to oral HIV PrEP among female sex workers living in South-Western Uganda
Nakiganda, L. J., Grulich, A. E., Poynten, I. M., Serwadda, D., Bazaale, J. M., Jin, F., & Bavinton, B. R. (2022) · PLoS ONE · doi:10.1371/journal.pone.0277226 · Cited by 9
Long-acting lenacapavir protects macaques against intravenous challenge with simian-tropic HIV
Swanstrom, A. E., Gorelick, R. J., Welker, J. L., Schmidt, F., Lu, B., Wang, K., Rowe, W., Breed, M. W., Killoran, K. E., Kramer, J. A., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104764 · Cited by 8
Perceived Risk Among Human Immunodeficiency Virus Serodiscordant Couples in East Africa Taking Oral Pre-Exposure Prophylaxis
Carroll, J. J., Heffron, R. A., Mugo, N., Ngure, K., Ndase, P., Asiimwe, S. B., Celum, C., & Baeten, J. M. (2016) · Sexually Transmitted Diseases · doi:10.1097/olq.0000000000000472 · Cited by 8
Long-term follow-up of HIV seroconverters in microbicide trials – rationale, study design, and challenges in MTN-015
Riddler, S. A., Husnik, M. J., Gorbach, P. M., Levy, L., Parikh, U. M., Livant, E., Pather, A., Makanani, B., Muhlanga, F., Kasaro, M. P., et al. (2016) · HIV Clinical Trials · doi:10.1080/15284336.2016.1212561 · Cited by 8
Factors Supporting and Hindering Adherence to Rectal Microbicide Gel Use with Receptive Anal Intercourse in a Phase 2 Trial
on behalf of the MTN-017 Protocol Team, Giguere, R., Rael, C. T., Sheinfil, A. Z., Balán, I. C., Brown, W., Ho, T., Dolezal, C. L., Leu, C., Liu, A., et al. (2017) · AIDS and Behavior · doi:10.1007/s10461-017-1890-7 · Cited by 8
Lactoferrin Nanoparticles Coencapsulated with Curcumin and Tenofovir Improve Vaginal Defense Against HIV-1 Infection
Lakshmi, Y. S., Kumar, P., Seetharam, D., & Kondapi, A. K. (2021) · Nanomedicine · doi:10.2217/nnm-2020-0347 · Cited by 8
Drug-releasing vaginal rings for HIV/STI and pregnancy prevention: a review of recent advances and clinical applications
Palanee‐Phillips, T., Baum, M. M., Moss, J. A., Clark, M. R., Nuttall, J. P., & Romano, J. (2021) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2020242 · Cited by 8
Long-Acting Injectable Preexposure Prophylaxis for HIV Prevention in South Africa: Is There a Will and a Way?
Landovitz, R. J., & Grinsztejn, B. G. J. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiv524 · Cited by 8
MicroCOSM: a model of social and structural drivers of HIV and interventions to reduce HIV incidence in high-risk populations in South AfricaPreprint
Johnson, L. F., Kubjane, M., & Moolla, H. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/310763 · Cited by 9
Motivators for oral PrEP uptake and adherence in the eThekwini municipality, KwaZulu-Natal
Basdav, J., Reddy, P., & Haffejee, F. (2023) · AIDS Care · doi:10.1080/09540121.2023.2208322 · Cited by 7
Lessons learnt from daily oral PrEP delivery to inform national planning for PrEP ring introduction for women in low-income and middle-income countries: a qualitative inquiry of international stakeholders
Heck, C. J., Dam, A., Yohannes, K., Deacon, J., Kripke, K. E., Meyers, K. A., Poku, O. B., Obermeyer, C., Wiant, S., Quigee, D., et al. (2024) · BMJ Global Health · doi:10.1136/bmjgh-2023-014709 · Cited by 7
Using participatory art-based methods to explore experiences and practices in sexual and reproductive health
Govender, E., Nota, P. B., Gumede, M., & Ngubane, N. (2024) · Methods in Psychology · doi:10.1016/j.metip.2024.100160 · Cited by 7

Authors: Marrazzo, J. M., Ramjee, G., Richardson, B. A., Gomez, K., Mgodi, N., Nair, G., Palanee, T., Nakabiito, C., van der Straten, A., Noguchi, L., Hendrix, C. W., Dai, J. Y., Ganesh, S., Mkhize, B., Taljaard, M., Parikh, U. M., Piper, J., Mâsse, B., Grossman, C., Rooney, J., Schwartz, J. L., Watts, H., Marzinke, M. A., Hillier, S. L., McGowan, I. M., & Chirenje, Z. M.
Affiliations: University of California, San Francisco (US)
Harborview Medical Center (US)
Family Health International 360 (US)
University of Zimbabwe (ZW)
Centre for the AIDS Programme of Research in South Africa (ZA)
University of Pittsburgh (US)
Johns Hopkins University (US)
South African Medical Research Council (ZA)
National Institutes of Health (US)
Eastern Virginia Medical School (US)
ORCID: Marrazzo, Jeanne M.
Richardson, Barbra A.
Gomez, Kailazarid
Mgodi, Nyaradzo
Nair, Gonasagrie
Nakabiito, Clemensia
Noguchi, Lisa
Hendrix, Craig W.
Dai, James Y.
Parikh, Urvi M.
Piper, Jeanna
Mâsse, Benoît
Rooney, James
Watts, Heather
Marzinke, Mark A.
Hillier, Sharon L.
McGowan, Ian M.
Chirenje, Z. Mike
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2015-02-05
Volume: 372
Issue: 6
Pages: 509-518
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1402269
PMC: PMC4341965
OpenAlex: W2044369525
Cited by: 1,296
References: 19
Citations by year: 2026: 32 · 2025: 54 · 2024: 59 · 2023: 78 · 2022: 93 · 2021: 143 · 2020: 125 · 2019: 139 · 2018: 122 · 2017: 140 · 2016: 175 · 2015: 131
FWCI: 147.62
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
ResearchSpace (University of KwaZulu-Natal) (submittedVersion)
Funders: National Institute of Allergy and Infectious Diseases (U01AI068633, UM1AI068615, UM1AI069422, UM1AI106707, UM1AI069436, P30AI094189, UM1AI069530, UM1AI069463, UM1AI069469)
Topics: Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
Keywords: tenofovir disoproxil fumarate, tenofovir/emtricitabine, HIV pre-exposure prophylaxis, HIV-1 prevention, women, women of reproductive age, antiretroviral resistance, tenofovir resistance, drug safety, adverse events, creatinine elevation
MeSH terms: Emtricitabine, Tenofovir, Adenine, Administration, Intravaginal, Administration, Oral, Adolescent, Adult, Deoxycytidine, Drug Therapy, Combination, Female, HIV Seropositivity, Humans, Middle Aged, Surveys and Questionnaires, HIV-1, HIV Infections, Africa South of the Sahara, Drug Resistance, Viral, Anti-Retroviral Agents, Medication Adherence, Young Adult, Organophosphonates, Pre-Exposure Prophylaxis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Tenofovir-based preexposure prophylaxis for HIV infection among African women.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks